# Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

> **NCT02061449** · PHASE1 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 3 (actual)

## Conditions studied

- Cutaneous T-cell Lymphoma

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** Poly ICLC
- **RADIATION:** Focal lesional radiation

## Key facts

- **NCT ID:** NCT02061449
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2018-11-05
- **Final completion:** 2018-11-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low Accrual
- **Last updated:** 2018-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02061449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02061449, "Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02061449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*